Regeneron and Bayer HealthCare announced results from their Phase 3 program of VEGF Trap-Eye (aflibercept ophthalmic injection solution) in patients with the neovascular form of age-related macular degeneration (wet AMD). This program, also known as the VIEW (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD) program, consists of two randomized, double-masked, Phase 3 trials evaluating VEGF Trap-Eye in over 2400 patients at sites around the world. The study designs for both trials are essentially identical. The primary endpoint was statistical non-inferiority in the proportion of patients who maintained (or improved) vision over 52 weeks compared to ranibizumab. In both studies, all regimens of VEGF Trap-Eye, including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
VEGF Trap-Eye is a fully human fusion protein, consisting of soluble VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).
For more information call (877) REGN-777 or visit www.regeneron.com.